This indicates that clinical efficacy of B‐cell depletion therapies is because of removal of B‐cell functions other than antibody production, such as antigen presentation, production of inflammatory cytokines, stimulation of autoproliferating CD4+ T cells, clearing of the EBV‐infected memory B‐cell pool or removal of a subset of proinflammatory CD20+ T cells, which have been identified in MS.105, 115, 116, 117, 118, 119. This evidence concerns the gene CD4 and myeloid sarcoma.